XML 98 R84.htm IDEA: XBRL DOCUMENT v3.26.1
SEGMENT INFORMATION - Schedule of Reconciliation of Significant Expense Categories (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 10 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Feb. 28, 2025
Feb. 27, 2025
Segment Reporting [Line Items]              
Total revenues $ 192,399 $ 181,099 $ 369,775 $ 350,022      
Stock-based compensation     28,497 30,025      
Amortization of acquired intangible assets 14,322 14,322 28,644 28,644      
Changes in the fair value of contingent consideration 1,663 (357) (614) (3,032)      
Legal settlement 0 0 0 7,000      
Total operating expenses 188,132 172,600 358,606 339,533      
Total other expense, net (1,712) (10,426) (3,616) (3,710)      
Income (loss) before income taxes 2,555 (1,927) 7,553 6,779      
Income tax benefit (expense) 2,098 (2,920) 16 (6,814)      
Net income (loss) 4,653 (4,847) 7,569 (35)      
Divestiture-related expenses 5,931 0 5,931 0      
Acquisition-related expenses 0 991 0 2,502      
GQ Bio Therapeutics GmbH              
Segment Reporting [Line Items]              
Percentage of voting interests acquired           81.00%  
Acquisition-related expenses 1,000   2,500        
Key employee holdback agreement             $ 7,800
Key employee holdback agreement payment period         3 years    
Key employee holdback recognition year one             50.00%
Key employee holdback recognition year two             30.00%
Key employee holdback recognition year three             20.00%
Payment for achievement of regulatory milestone 600 1,100 1,500 1,500      
GQ Bio Therapeutics GmbH | GQ Bio Therapeutics GmbH              
Segment Reporting [Line Items]              
Percentage of voting interests acquired           81.00%  
Reportable Segment              
Segment Reporting [Line Items]              
Total revenues 192,399 181,099 369,775 350,022      
Adjusted cost of goods sold 42,355 32,663 77,125 65,253      
Adjusted research and development 27,053 24,686 52,415 47,787      
Adjusted selling and marketing 52,117 50,964 110,283 106,535      
Adjusted general and administrative 29,148 26,231 54,860 46,840      
Stock-based compensation 14,958 15,472 28,497 30,025      
Amortization of acquired intangible assets 14,322 14,322 28,644 28,644      
Divestiture and acquisition-related expenses 6,516 2,098 7,396 3,960      
Changes in the fair value of contingent consideration 1,663 (357) (614) (3,032)      
Legal settlement 0 0 0 7,000      
Decommissioning of manufacturing suite 0 6,521 0 6,521      
Total operating expenses 188,132 172,600 358,606 339,533      
Total other expense, net (1,712) (10,426) (3,616) (3,710)      
Income (loss) before income taxes 2,555 (1,927) 7,553 6,779      
Income tax benefit (expense) 2,098 (2,920) 16 (6,814)      
Net income (loss) 4,653 $ (4,847) 7,569 $ (35)      
Divestiture-related expenses $ 5,900   $ 5,900